The trading price of Progenity, Inc. (NASDAQ:PROG) floating higher at last check on Monday, Jun 07, closing at $2.2, 2.57% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $2.2000 and $2.2900. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 0. In examining the 52-week price action we see that the stock hit a 52-week high of $15.92 and a 52-week low of $2.04. Over the past month, the stock has suffered -28.8% in value.
Progenity, Inc., whose market valuation is $127.6 Million at the time of this writing, is expected to release its quarterly earnings report Aug 11, 2021- Aug 16, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.8 per share this quarter, however they have predicted annual earnings per share of -$2.1 for 2021 and -$1.29 for 2022. It means analysts are expecting annual earnings per share growth of -0.7% this year and -0.39% next year.
Analysts have forecast the company to bring in revenue of $20.45 Million for the quarter, with the likely lows of $16.19 Million and highs of $25.65 Million. The average estimate suggests sales will likely up by 18.4% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $73.77 Million. The company’s revenue is forecast to drop by -0.7% over what it did in 2020.
On the technical side, indicators suggest PROG has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned PROG a recommendation rating is 5. Out of them, 2 rate it a Hold, while 2 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged Progenity, Inc. (PROG) as Underperform, while 1 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that PROG’s price is currently -6.85% off the SMA20 and -28.8% off the SMA50. The RSI metric on the 14-day chart is currently showing 40.66, and weekly volatility stands at 13.64%. When measured over the past 30 days, the indicator reaches 12.07%. Progenity, Inc. (NASDAQ:PROG)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 0.29. With analysts defining $2-$12 as the low and high price targets, we arrive at a consensus price target of $5.2 for the trailing 12-month period. The current price is about -11.5% off the estimated low and 430.97% off the forecast high, based on this estimate. Investors will be thrilled if PROG’s share price rises to $3, which is the median consensus price. At that level, PROG’s share price would be +32.74% above current price.
To see how Progenity, Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: PROG stock’s performance was +2.57% at last check in today’s session, and 0% in the past year, while Zoetis Inc Cl A (ZTS) has been trading +0.55% in recent session and positioned +24.68% higher than it was a year ago. Another comparable company Takeda Pharmaceutical Co. Ltd (TAK) saw its stock trading 0.84% higher in today’s session but was down -9.13% in a year. Furthermore, Catalent Inc (CTLT) showed an increase of 2.57% today while its price kept declining at 0% over the past year. Progenity, Inc. has a P/E ratio of 0, compared to Zoetis Inc Cl A’s 47.24 and Takeda Pharmaceutical Co. Ltd’s 31.79. Also during today’s trading, the S&P 500 Index has soared -0.31%, while the Dow Jones Industrial also saw a negative seesion, down -0.34% today.
An evaluation of the daily trading volume of Progenity, Inc. (NASDAQ:PROG) indicates that the 3-month average is 662.98 Million. However, this figure has declined over the past 10 days to an average of 2.9 Million.
Currently, records show that 60.34 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 25.42% of outstanding shares, whereas institutions hold 62.07%. The stats also highlight that short interest as of April 14, 2021, stood at 3.01 Million shares, resulting in a short ratio of 7.67 at that time. From this, we can conclude that short interest is 4.99% of the company’s total outstanding shares. It is noteworthy that short shares in April were down slightly from the previous month’s figure, which was 3.05 Million. However, since the stock’s price has seen -58.57% year-to-date, investors’ interest is likely to be reignited due to its potential to move higher ahead.